Compare Intuitive Surgical, Inc. (ISRG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Intuitive Surgical, Inc. trades at $405.5 (market cap $141.75B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B). The key difference: Intuitive Surgical, Inc. is far larger — about 78.3× Recursion Pharmaceuticals Inc's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ISRG | RXRX | |
|---|---|---|
Market Cap | $141.75B | $1.81B |
Sector | Health | Health |
52-Week High | $592.85 | $6.79 |
52-Week Low | $332.02 | $2.84 |
Enterprise Value | $136.53B | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
